EMAIL THIS PAGE TO A FRIEND

mAbs

Structure-guided residence time optimization of a dabigatran reversal agent.


PMID 26047352

Abstract

Novel oral anticoagulants are effective and safe alternatives to vitamin-K antagonists for anticoagulation therapy. However, anticoagulation therapy in general is associated with an elevated risk of bleeding. Idarucizumab is a reversal agent for the direct thrombin inhibitor, dabigatran etexilate (Pradaxa®) and is currently in Phase 3 studies. Here, we report data on the antibody fragment aDabi-Fab2, a putative backup molecule for idarucizumab. Although aDabi-Fab2 completely reversed effects of dabigatran in a rat model in vivo, we observed significantly reduced duration of action compared to idarucizumab. Rational protein engineering, based on the X-ray structure of aDabi-Fab2, led to the identification of mutant Y103W. The mutant had optimized shape complementarity to dabigatran while maintaining an energetically favored hydrogen bond. It displayed increased affinity for dabigatran, mainly driven by a slower off-rate. Interestingly, the increased residence time translated into longer duration of action in vivo. It was thus possible to further enhance the efficacy of aDabi-Fab2 based on rational design, giving it the potential to serve as a back-up candidate for idarucizumab.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

220116
2-Hydroxybutyric acid sodium salt, 97%
C4H7NaO3
A0293 Anti-Human IgG (Fab specific)−Peroxidase antibody produced in goat, affinity isolated antibody
SAB3701274
Anti-Human IgG (Fc specific), F(ab′)2 fragment, highly cross adsorbed antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701284 Anti-Human IgG (Fc specific), highly cross adsorbed antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701289 Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody produced in goat, affinity isolated antibody, buffered aqueous solution
I9885 Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody produced in goat, affinity isolated antibody, lyophilized powder
SAB3701314 Anti-Human IgG (H+L), F(ab) fragment antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701247 Anti-Human IgG F(ab′)2 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701246 Anti-Human IgG F(ab′)2, F(ab′)2 fragment, highly cross absorbed antibody produced in goat, affinity isolated antibody, buffered aqueous solution
791725
Citric acid, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99.5%
C6H8O7
C2404
Citric acid, anhydrous, cell culture tested, plant cell culture tested
C6H8O7
251275
Citric acid, ACS reagent, ≥99.5%
C6H8O7
C83155
Citric acid, 99%
C6H8O7
C0759
Citric acid, 99%
C6H8O7
27487
Citric acid, BioUltra, anhydrous, ≥99.5% (T)
C6H8O7
W230618
Citric acid, ≥99.5%, FCC, FG
C6H8O7